Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page
- Check6 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3. This appears to be a minor internal update with no user-facing changes to the Study Details page.SummaryDifference0.0%

- Check13 days agoChange DetectedCosmetic UI/Layout changes observed with no modification to core study details or outcomes.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new Revision: v3.4.2 tag was added. A non-critical funding/operating status notice was removed; core trial content and page functionality remain unchanged.SummaryDifference0.2%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operating status was added, and the site revision was updated from 3.4.0 to 3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check48 days agoChange DetectedUI and metadata updates include showing a glossary option and adding metadata fields such as Results First Posted, Certification/Extension First Posted, Last Update Submitted that Met QC Criteria, and Last Update Posted, with the revision noted as v3.4.0; older related fields were removed.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no user-facing study details appear to be affected.SummaryDifference0.0%

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.